Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation

[1]  Martin Eisenacher,et al.  The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..

[2]  S. Henderson,et al.  TBK1 and IKKε prevent TNF-induced cell death by RIPK1 phosphorylation , 2018, Nature Cell Biology.

[3]  C. Nadal,et al.  Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial , 2018, JAMA oncology.

[4]  L. Kremer,et al.  New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness , 2017, Front. Immunol..

[5]  J. Chamberland,et al.  Retromer revisited: Evolving roles for retromer in endosomal sorting , 2017, The Journal of cell biology.

[6]  L. Johannes.  Shiga Toxin—A Model for Glycolipid-Dependent and Lectin-Driven Endocytosis , 2017, Toxins.

[7]  C. Antonescu,et al.  Selective regulation of clathrin-mediated epidermal growth factor receptor signaling and endocytosis by phospholipase C and calcium , 2017, Molecular biology of the cell.

[8]  G. Woude,et al.  Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms , 2017, Molecular Cancer Therapeutics.

[9]  Shigeki Watanabe,et al.  Fast and ultrafast endocytosis. , 2017, Current opinion in cell biology.

[10]  D. Hochhauser,et al.  Stress-specific p38 MAPK activation is sufficient to drive EGFR endocytosis but not its nuclear translocation , 2017, Journal of Cell Science.

[11]  F. Ciardiello,et al.  Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells , 2017, Oncotarget.

[12]  G. Fairn,et al.  The acyltransferase LYCAT controls specific phosphoinositides and related membrane traffic , 2017, Molecular biology of the cell.

[13]  J. Shillcock,et al.  Mechanism of Shiga Toxin Clustering on Membranes , 2016, ACS nano.

[14]  E. Stang,et al.  A combination of two antibodies recognizing non‐overlapping epitopes of HER2 induces kinase activity‐dependent internalization of HER2 , 2016, Journal of cellular and molecular medicine.

[15]  K. Muro,et al.  Phase I dose-escalation trial of Sym004, a mixture of two anti-EGFR antibodies, in Japanese patients with advanced solid tumors. , 2016 .

[16]  Xiaojun Tan,et al.  Stress-Induced EGFR Trafficking: Mechanisms, Functions, and Therapeutic Implications. , 2016, Trends in cell biology.

[17]  Amanda C. Schierz,et al.  canSAR: an updated cancer research and drug discovery knowledgebase , 2015, Nucleic acids research.

[18]  Y. Kalaidzidis,et al.  APPL endosomes are not obligatory endocytic intermediates but act as stable cargo-sorting compartments , 2015, The Journal of cell biology.

[19]  B. Goud,et al.  Integrin endosomal signalling suppresses anoikis , 2015, Nature Cell Biology.

[20]  A. Jones,et al.  Receptor Crosslinking: A General Method to Trigger Internalization and Lysosomal Targeting of Therapeutic Receptor:Ligand Complexes , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  D. Hochhauser,et al.  WASH and Tsg101/ALIX-dependent diversion of stress-internalized EGFR from the canonical endocytic pathway , 2015, Nature Communications.

[22]  Y. Yarden,et al.  Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer , 2015, Science Signaling.

[23]  T. P. Neufeld,et al.  Autophagosome–lysosome fusion is independent of V-ATPase-mediated acidification , 2015, Nature Communications.

[24]  J. Machiels,et al.  A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck , 2015, Cancer Chemotherapy and Pharmacology.

[25]  L. Johannes,et al.  Endophilin-A2 functions in membrane scission in clathrin-independent endocytosis , 2014, Nature.

[26]  Brendan MacLean,et al.  MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments , 2014, Bioinform..

[27]  S. Mayor,et al.  Clathrin-independent pathways of endocytosis. , 2014, Cold Spring Harbor perspectives in biology.

[28]  J. Rappoport,et al.  Interdependent epidermal growth factor receptor signalling and trafficking. , 2014, The international journal of biochemistry & cell biology.

[29]  A. Audhya,et al.  The ESCRT machinery: From the plasma membrane to endosomes and back again , 2014, Critical reviews in biochemistry and molecular biology.

[30]  Christian H. Ahrens,et al.  Protter: interactive protein feature visualization and integration with experimental proteomic data , 2014, Bioinform..

[31]  J. Heath,et al.  The non-receptor tyrosine kinase Ack1 regulates the fate of activated EGFR by inducing trafficking to the p62/NBR1 pre-autophagosome , 2014, Journal of Cell Science.

[32]  Amanda C. Schierz,et al.  canSAR: an updated cancer research and drug discovery knowledgebase , 2015, Nucleic Acids Res..

[33]  P. Harari,et al.  Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers , 2013, Molecular Cancer Therapeutics.

[34]  N. Tebbutt,et al.  Targeting the ERBB family in cancer: couples therapy , 2013, Nature Reviews Cancer.

[35]  Sandra L Schmid,et al.  Advances in analysis of low signal-to-noise images link dynamin and AP2 to the functions of an endocytic checkpoint. , 2013, Developmental cell.

[36]  Amber L. Couzens,et al.  The CRAPome: a Contaminant Repository for Affinity Purification Mass Spectrometry Data , 2013, Nature Methods.

[37]  A. Ciliberto,et al.  Threshold-controlled ubiquitination of the EGFR directs receptor fate , 2013, The EMBO journal.

[38]  D R Mani,et al.  Refined Preparation and Use of Anti-diglycine Remnant (K-ε-GG) Antibody Enables Routine Quantification of 10,000s of Ubiquitination Sites in Single Proteomics Experiments* , 2012, Molecular & Cellular Proteomics.

[39]  I. Madshus,et al.  Cetuximab in combination with anti-human IgG antibodies efficiently down-regulates the EGF receptor by macropinocytosis. , 2012, Experimental cell research.

[40]  Kerstin Pingel,et al.  50 Years of Image Analysis , 2012 .

[41]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[42]  P. S. Andersen,et al.  Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor , 2011, mAbs.

[43]  S. Schüller.  Shiga Toxin Interaction with Human Intestinal Epithelium , 2011, Toxins.

[44]  Jamie B. Spangler,et al.  Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling , 2010, Proceedings of the National Academy of Sciences.

[45]  T. Lawrence,et al.  Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. , 2010, Cancer research.

[46]  L. Johannes,et al.  Shiga toxins — from cell biology to biomedical applications , 2010, Nature Reviews Microbiology.

[47]  M. Sudol,et al.  HECT E3 Ubiquitin Ligase Nedd4-1 Ubiquitinates ACK and Regulates Epidermal Growth Factor (EGF)-Induced Degradation of EGF Receptor and ACK , 2010, Molecular and Cellular Biology.

[48]  C. Pyke,et al.  Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. , 2010, Cancer research.

[49]  G. Carpenter,et al.  Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor. , 2009, Cancer research.

[50]  Scott A. Brown,et al.  Analysis of nondegradative protein ubiquitylation with a monoclonal antibody specific for lysine-63-linked polyubiquitin , 2008, Proceedings of the National Academy of Sciences.

[51]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[52]  P. P. Di Fiore,et al.  Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. , 2008, Developmental cell.

[53]  Zhixiang Wang,et al.  A Tale of Two Cbls: Interplay of c-Cbl and Cbl-b in Epidermal Growth Factor Receptor Downregulation , 2008, Molecular and Cellular Biology.

[54]  Katharina Gaus,et al.  Shiga toxin induces tubular membrane invaginations for its uptake into cells , 2007, Nature.

[55]  Roger L. Williams,et al.  The emerging shape of the ESCRT machinery , 2007, Nature Reviews Molecular Cell Biology.

[56]  Rebecca S. Dise,et al.  p38 kinase regulates epidermal growth factor receptor downregulation and cellular migration , 2006, The EMBO journal.

[57]  M. Mann,et al.  In-gel digestion for mass spectrometric characterization of proteins and proteomes , 2006, Nature Protocols.

[58]  F. Cordelières,et al.  A guided tour into subcellular colocalization analysis in light microscopy , 2006, Journal of microscopy.

[59]  Kanyawim Kirtikara,et al.  Sulforhodamine B colorimetric assay for cytotoxicity screening , 2006, Nature Protocols.

[60]  C. Futter,et al.  Distinct roles for Tsg101 and Hrs in multivesicular body formation and inward vesiculation. , 2006, Molecular biology of the cell.

[61]  Xuejun Jiang,et al.  Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. , 2006, Molecular cell.

[62]  C. Futter,et al.  EGF stimulates annexin 1‐dependent inward vesiculation in a multivesicular endosome subpopulation , 2006, The EMBO journal.

[63]  E. Kornilova,et al.  Two different stages of epidermal growth factor (EGF) receptor endocytosis are sensitive to free ubiquitin depletion produced by proteasome inhibitor MG132 , 2005, Cell biology international.

[64]  P. Transidico,et al.  Clathrin-independent endocytosis of ubiquitinated cargos. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Y. Yarden,et al.  Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Stephen E. Moss,et al.  Annexin 11 is required for midbody formation and completion of the terminal phase of cytokinesis , 2004, The Journal of cell biology.

[67]  Stefan Matile,et al.  Role of LBPA and Alix in Multivesicular Liposome Formation and Endosome Organization , 2004, Science.

[68]  J. Surrey,et al.  Couples Therapy , 2000 .

[69]  S. Schmid,et al.  Induction of mutant dynamin specifically blocks endocytic coated vesicle formation , 1994, The Journal of cell biology.

[70]  Y. Moriyama,et al.  Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. , 1991, The Journal of biological chemistry.

[71]  J. Slot,et al.  A new method of preparing gold probes for multiple-labeling cytochemistry. , 1985, European journal of cell biology.

[72]  L. Johannes,et al.  Bending "on the rocks"--a cocktail of biophysical modules to build endocytic pathways. , 2014, Cold Spring Harbor perspectives in biology.

[73]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .